Revance Therapeutics -14% on Preliminary Q4, FY24 Outlook

$Revance Therapeutics(RVNC.US)$ Monday showed sales volumn rose 22% in Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. The firm predicted an unaudited Q4 and full-year 2023 revenue between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively.